Tuberous sclerosis preclinical studies: timing of treatment, combination of a rapamycin analog (CCI-779) and interferon-gamma, and comparison of rapamycin to CCI-779 [0.03%]
tuberous sclerosis的前临床研究：治疗时机，雷帕霉素类似物（CCI-779）和干扰素-γ联合应用以及雷帕霉素与CCl-779对比研究
Michael P Messina,Aubrey Rauktys,Laifong Lee et al.
Michael P Messina et al.
Background: Tuberous Sclerosis Complex (TSC) is an autosomal dominant hamartoma disorder with variable expression for which treatment options are limited. TSC is caused by a mutation in either the TSC1 or TSC2 genes, whos...
Comparative Study
BMC pharmacology. 2007 Nov 6:7:14. DOI:10.1186/1471-2210-7-14 2007
Impact of imatinib on the pharmacokinetics and in vivo efficacy of etoposide and/or ifosfamide [0.03%]
伊马替尼对依托泊苷和/或异环磷酰胺的药代动力学及抗肿瘤作用的影响
Keyvan Rezaï,François Lokiec,Isabelle Grandjean et al.
Keyvan Rezaï et al.
Background: Using a human small cell lung cancer (SCLC) xenografted in nude mice, we have previously reported enhanced tumor growth inhibition following chemotherapy in combination with imatinib (STI571). We therefore inv...
Ciclesonide uptake and metabolism in human alveolar type II epithelial cells (A549) [0.03%]
佛索洛莫司在人肺泡Ⅱ型上皮细胞(A549)中的摄取与代谢
Takashi Nonaka,Rüdiger Nave,Nigel McCracken et al.
Takashi Nonaka et al.
Background: Ciclesonide is a novel inhaled corticosteroid for the treatment of airway inflammation. In this study we investigated uptake and in vitro metabolism of ciclesonide in human alveolar type II epithelial cells (A...
Comparative Study
BMC pharmacology. 2007 Sep 27:7:12. DOI:10.1186/1471-2210-7-12 2007
Gene expression profiling reveals effects of Cimicifuga racemosa (L.) NUTT. (black cohosh) on the estrogen receptor positive human breast cancer cell line MCF-7 [0.03%]
基因表达谱分析揭示了Cimicifuga racemosa（L．）NUTH．（黑升麻）对人乳腺癌细胞系MCF-7的作用
Friedemann Gaube,Stefan Wolfl,Larissa Pusch et al.
Friedemann Gaube et al.
Background: Extracts from the rhizome of Cimicifuga racemosa (black cohosh) are increasingly popular as herbal alternative to hormone replacement therapy (HRT) for the alleviation of postmenopausal disorders. However, the...
An integrative in silico approach for discovering candidates for drug-targetable protein-protein interactions in interactome data [0.03%]
整合的计算方法，在蛋白质互作组数据中发现候选药物可作用的蛋白质-蛋白质相互作用靶点
Nobuyoshi Sugaya,Kazuyoshi Ikeda,Toshiyuki Tashiro et al.
Nobuyoshi Sugaya et al.
Background: Protein-protein interactions (PPIs) are challenging but attractive targets for small chemical drugs. Whole PPIs, called the 'interactome', have been emerged in several organisms, including human, based on the ...
Sodium valproate stimulates potassium and chloride urinary excretion in rats: gender differences [0.03%]
valsproate刺激大鼠钾和氯的尿排泄：性别差异的影响
Eitaute Jakutiene,Jurgita Grikiniene,Arunas Vaitkevicius et al.
Eitaute Jakutiene et al.
Background: The diuretic effect of valproates and its relation to urinary potassium (K+) and chloride (Cl-) excretion have not yet been investigated, so the aim of this study was to evaluate the influence of a single dose...
Structural and functional definition of the specificity of a novel caspase-3 inhibitor, Ac-DNLD-CHO [0.03%]
一种新型caspase-3抑制剂Ac-DNLD-CHO的特异性的结构和功能定位研究
Atsushi Yoshimori,Junichi Sakai,Satoshi Sunaga et al.
Atsushi Yoshimori et al.
Background: The rational design of peptide-based specific inhibitors of the caspase family members using their X-ray crystallographies is an important strategy for chemical knockdown to define the critical role of each en...
Uptake and metabolism of ciclesonide and retention of desisobutyryl-ciclesonide for up to 24 hours in rabbit nasal mucosa [0.03%]
环索奈德的吸收及代谢以及去异丁基-环索奈德在兔鼻粘膜中24小时蓄积情况
Hideyuki Sato,Ruediger Nave,Takashi Nonaka et al.
Hideyuki Sato et al.
Background: The nasal tissue uptake and metabolism of ciclesonide, a new-generation corticosteroid under investigation for treatment of allergic rhinitis, to its active metabolite, desisobutyryl-ciclesonide (des-CIC), was...
Abstracts of the 2nd International Conference of cGMP Generators, Effectors and Therapeutic Implications. Potsdam, Germany. June 10-12, 2005 [0.03%]
第二届环磷腺苷生成物、效应器和治疗意义国际会议概况 马普陀堂，德国 二零零五年六月十日至十二日
Sarah E Abbey-Hosch,Dmitri Smirnov,Lincoln R Potter
Sarah E Abbey-Hosch